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Isolated hepatic perfusion in the pig with TNF-OC with 
and without melphalan
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Summary Isolated limb perfusion with tumour necrosis factor alpha (TNF-a) and melphalan is well tolerated and highly effective in 
irresectable sarcoma and melanoma. No data are available on isolated hepatic perfusion (IHP) with these drugs for irresectable hepatic 
malignancies. This study was undertaken to assess the feasibility of such an approach by analysing hepatic and systemic toxicity of IHP with 
TNF-a with and without melphalan in pigs. Ten healthy pigs underwent IHP. After vascular isolation of the liver, inflow catheters were placed 
in the hepatic artery and portal vein, and an outflow catheter was placed in the inferior vena cava (IVC). An extracorporeal veno-venous 
bypass was used to shunt blood from the lower body and intestines to the heart. The liver was perfused for 60 min with (1) 50 (.ig kg-1 TNF-a 
(n = 5), (2) 50 |^ g kg-1 T N F -a  plus 1 mg kg-1 melphalan (n = 3) or (3) no drugs (n = 2). The liver was washed with macrodex before restoring 
vascular continuity. All but one pigs tolerated the procedure well. Stable perfusion was achieved in all animals with median perfusate TNF-a 
levels of 5.1 ± 0.78 x 106 pg ml-1 (± s.e.m). Systemic leakage of TN F-a  from the perfusate was consistently <0 .02% . Following IHP, a 
transient elevation of systemic T N F -a  levels was observed in groups 1 and 2 with a median peak level of 23 ± 3 x 103 pg ml-1 at 10 min after 
washout, which normalized within 6 h. No significant systemic toxicity was observed. Mild transient hepatotoxicity was seen to a similar extent 
in all animals, including controls. IHP with TN F-a with(out) melphalan in pigs is technically feasible, results in minimal systemic drug exposure 
and causes minor transient disturbances of liver biochemistry and histology.
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The liver is the commonest site o f  dissemination in patients with 
colorectal cancer (Bengmark, 1969; Wagner, 1984; Strangl, 1994). 
Five-year survival rates o f  up to 35% have been reported for 
patients amenable for partial hepatic resection (Hughes, 1986; 
Scheele, 1990; Van O oyen, 1992; Sugihara, 1993; Que, 1994). 
Unfortunately, the vast majority o f colorectal metastases confined  
to the liver are considered to be unresec table (Greenway, 1988; 
Cady, 1991; Genari, 1992). In addition, system ic chemotherapy 
has so far failed to provide satisfactory results in these cases 
(Kemeny, 1983, 1987). Therefore, it is mandatory to develop  
novel strategies to obtain tumour control in the liver.
The concept of locoregional administration of chemotherapy is 
aimed at achieving high local concentrations while minimizing  
systemic drug levels in an attempt to reduce dose-limiting side-
This might ance anti-tumour efficacy as
dose-response curves have been described for most chemothera­
peutic agents (Frei, 1980; Canellos, 1987). Several techniques 
have been developed for regional therapy o f  hepatic malignancies, 
of which hepatic artery infusion (HAI) has becom e most widely  
used (Sullivan, 1964; Pentecost, 1993; De Takats, 1994). Although  
HAI has been shown to improve short-term tumour response rates
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over systemic chemotherapy, it only slightly affects survival,
while significant dose-limiting has been encountered
(Kemeny, 1987; Pentecost, 1993; De Takats, 1994; Chang, 1987). 
Alternatively, isolated hepatic perfusion (IHP), including total
at ion o f  the liver, has been reported to significantly 
increase intrahepatic drug concentrations when compared with 
HAI, while maintaining sufficiently low system ic drug levels 
(Aigner, 1982; Skibba, 1983; De Brauw, 1988; Murinelli, 1991; 
Radnell, 1990). However, large animal studies have revealed 
systemic leakage o f  the perfused anti-tumour agent owing to 
incomplete vascular isolation in up to 20% o f animals (Sindelar, 
1985; Van de Velde, 1986). Although incidental clinical reports on 
IMP have confirmed its potential use in humans (Aigner, 1988; 
Skibba, 1988; Hafstrom, 1994), it is clear that optimization of the 
IHP methodology is needed. In addition, a drug(s) that would 
provide optimal anti-tumour activity in the 
present unknown.
High-do.se tumour necrosis factor alpha (TNF-(X) has been 
shown to be
* is at
tumoricidal both in vitro in vivo
(Alexander, 1991; JiUiltela, 1991; Sidhu, 1993). Many phase 1 and 
II studies have demonstrated that systemic administration ol’TNF- 
(X in man results in considerable dose-limiting toxicity at dose 
levels at which no anti-tumour activity is
other hand, isolated limb 
with high-dose T N F -a  in combination
melphalan has recently been documented to be.i e 
in patients with irreseett
%  I
I  f i a t i *
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sarcomas and in patients with stage III melanoma (Eggermont, and passed into the retrohepatic IVC. These two catheters were
1996«,/j; Li6nard, 1994). Although the exact mechanism of the connected to the extracorporeal circuit (see below) and, after
anti-tumour action by TNF-a is unknown, endothelial injury of the clamping of the suprahepatic IVC and the hepatic artery (HA),
tumour-associated vasculature has been suggested to play a pivotal portal liver perfusion was allowed immediately in an attempt to
role in inducing tumour necrosis (Watanabe, 1988; Renard, 1994; minimize anoxic liver damage (first anoxia time). Finally, the HA
Cid, 1994). Thus, TNF-a may be effective against any histological was cannulated with an 8F catheter, which was subsequently
tumour vaxiant, provided that the tumour has a well-developed connected, thus completing the isolated liver perfusion circuit. The
vascular bed. extracorporeal perfusion circuit consisted of a double head roller
It is not known whether intrahepatic administration of TNF-a pump, VPCML membrane oxygenator with integrated heat
via IHP is feasible with a satisfactory degree of safety. It is exchanger and reservoir, and arterial blood filters, analogous to the
possible that TNF-a might induce significant hepatotoxicity as extracorporeal circuit used during cardiopulmonary bypass proce-
Kupffer cells are known to release various cytokines in response to dures. The circuit was primed with 500 ml of colloid solution
TNF-a exposure (Shirahama, 1988; Busam, 1990). The present (Haemacel) and 500 ml of porcine blood. In addition, sodium
study in healthy pigs was performed to determine the effects of hydrocarbonate 8.4% was added to the priming infusion (15-
IHP with TNF-a, with and without melphalan, with emphasis on 20 ml). Portal and arterial flow rates and pressures, together with
hepatic and systemic toxicity. For this purpose, a modification of the oxygen saturation levels in the perfusate, were recorded as
previously reported IHP techniques was developed and tested.
MATERIALS AND METHODS
Isolated hepatic perfusion
Ten healthy pigs weighing 25-33 kg (median 30 kg) were used. 
All animals received humane care in compliance with the guide­
lines on animal welfare of the Erasmus University, Rotterdam. 
General anaesthesia was induced and maintained with pavulon 
and fentanyl. Before surgery, all pigs received 0.1 ml kg*1 
Depomycine, consisting of 200 000 IU ml-1 of procaine penicillin 
and 200 mg mb1 of dihydrostreptomycin. In all animals, an arterial 
line was introduced into the right carotid artery; a tunnelled 
double-lumen central venous catheter and Swan-Ganz catheter 
were placed in the right external and internal jugular veins respec­
tively. In addition, the left external jugular vein was dissected in 
preparation for the veno-venous bypass shunt (see below). Via a 
midline abdominal incision, the liver was mobilized by transecting 
all ligaments, and the supra- and infrahepatic inferior vena cava 
(IVC) were dissected and encircled. The hepatoduodenal ligament 
was meticulosuly dissected preserving the common bile duct, 
coeliac trunk, portal vein (PV) and hepatic artery (HA). Branches 
of the -PV and the HA, particularly those arterial branches running 
towards duodenum and stomach, were ligated as needed to obtain 
complete vascular isolation of the liver. The right common iliac 
vein was dissected free. After heparinization with 2 mg kg 1 
heparin, a veno-venous bypass circuit (VVB) was established 
using an inverted V-shaped cannula to shunt mesenteric, renal and 
lower extremity blood around the liver back to the heart. For this 
purpose, a 20F cannula was introduced into the right common iliac 
vein, passed into the infrarenal IVC, and the free end was 
connected with one of the two lower limbs of the inverted Y. Next, 
the left jugular vein was cannulated (20F) and connected to the 
upper limb of the inverted Y. To complete the VVB, the distal PV 
was clamped, cannulated (20F) and connected with the remaining 
lower limb. Directly before opening the VVB, a clamp was placed 
on the infrahepatic suprarenal IVC, proximal from the cannula tip. 
The VVB flow was aided by a centrifugal pump (Medtronic, 
Biomedics, USA) in a manner identical to the technique currently 
used during liver transplantation procedures (Starzl, 1990). The 
liver perfusion circuit was established by introducing a 20F 
cannula into the hepatic side of the PV. A 24F venous outflow 
catheter was placed into the suprarenal, infrahepatic IVC via a 
longitudinal phlebotomy (including the pericaval hepatic tissue)
indicated by the heart-lung machine. The flow rates in the VVB 
shunt were also documented. In addition, the portal flow rates 
were measured before and immediately after IHP using an 8-mm 
35B548 flow probe (Transonic Systems, Ithaca, NY, USA) 
connected to a Transonic T206X flowmeter (AB Medical, 
Roermond, The Netherlands). Once stable perfusion was estab­
lished, as judged by the reservoir level, absence of systemic 
leakage from the IHP circuit was confirmed by injection of 1 cm3 
of a 1:10 dilution of fluorescein into the arterial circuit, followed 
by illumination with a UV (Woods) lamp. The perfusate was 
heated to 40°C using a cooler/heater device and was kept at 
> 39°C throughout the drug perfusion period. After 60 min of 
perfusion the liver was washed with Macrodex (> 1500 ml) until 
the fluid from the hepatic veins was clear. In order to restore phys­
iological hepatic perfusion, the HA was decannulated and repaired 
with Prolene 7-0, whereafter the HA and VCI clamps (second 
anoxia time) were released. Next, the ICV and PV were decannu­
lated and sutured (Prolene 5-0). The VVB was further dismantled 
by decannulating and ligating the left internal jugular vein and 
right common iliac vein respectively. Heparin was reversed by 
injection of protamine. Pigs were sacrificed 4-6 weeks after IHP.
Table 1 Technical data"
Control 
(n = 2)
TNF
(n = 5)
TNF/melphalan 
(n = 3)
Anoxic period (min) 
First 
Second
0 ± 0 
6 ± 1.4
1 ± 2 
13 ± 3
0 ± 0 
13 ± 3
Flow rate VVB (ml min ') 11251:176 1053 ± 50 1117 ± 29
Perfusion pressure (mmHg) 
HA 
PV
125 ±35 
33 ±4
110 ± 46 
38 ± 6
178154 
43 ± 6
Perfusion flow rate (ml min*1) 
HA 
PV
225 ± 14 
470 ± 42
237± 121 
350 ± 71
178121 
407 1 55
Perfusate oxygen saturation (%) 77 ±2 73 ± 5 7211
“Technical perfusion data as indicated by pump and heart-lung machine. 
Data are presented as means ± s.e.m. First anoxic period Is defined as time 
between clamping and portal perfusion; second anoxic period as time 
between Initiation of wash out and arterial recirculation.
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Figure 1 Course of liver biochemistry parameters as a function of time (days) following hyperthermic isolated hepatic perfusion (IHP) in pigs on day 0. 
Error bars have been omitted for reasons of clarity. Standard deviations never exceeded 10% of the mean values depicted. -B -, Control; +, TNF;
TNF + melphalan
Drugs
Recombinant human tumour necrosis factor alpha (rhTNF-a)
Sampling schedule
< f 
c as sí 0 (i.e. upon
(0.2 mg per ampoule) was a kind gift from Boehringer lngelheim , 30, 45 and 60 min. Systemic blood samples were collected the day
Germany. The cytostatic drug melphalan (Alkeran) was obtained 
as a sterile powder (100 mg) that was dissolved aseptically using 
solvent and diluent by Burroughs Wellcome (London, UK).
Treatment schedule
In five pigs, a 60-min hyperthermic IHP was performed with 
rhTNF-a (50 |ig  kg 1 ) alone, while three pigs were treated by IHP 
with rhTNF-a (50 |ig  k g '1) plus melphalan ( I mg kg '). T N F  was 
administered as a bolus in the arterial line o f  the perfusion circuit; 
melphalan was given directly following the rhTNF bolus. In two 
control pigs, no drugs were added (sham group).
before IHP, during IHP at t -  0, 15, 30, 45 and 60 min and after
1, 1 0 ,3 0 ,6 0 ,  120 and 480  min, days 1, 3, and 7 and
s were centr at r.p.m.
for 5 min. Supernatant» were stored at -7 0 °C  until analysis. Biliary
ox.imateIy 5 -1 0  ml) were taken by direct puncture of  
the gall bladder before IHP, immediately alter IHP and upon
TNF-a assay
TNF-a was measured by a sandwich-type ELISA using two
monoclonal antibodies (Department o f  Immune Reagents, Central
© Cancer Research Campaign 1997 British Journal of Cancer (1997) 75(10), 1447-1453
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Laboratory o f  Blood Transfusion, Amsterdam, Netherlands) raised 
against rhTNF-a (courtesy o f  Dr A Creasey, Chiron, Emeryville, 
CA, USA). One MAb (MAb CLB-TNFa-7) was used for coating 
at a concentration o f  2 |ig  m b 1; the second MAb (MAb CLB- 
T N F a-5) was biotinylated and used in combination with strepta- 
vidin poly-horseradish peroxidase conjugate to detect bound 
TN F-a. Stimulated human mononuclear cell supernatant was used 
as a standard for comparison with purified rhTNF-a. Results were 
expressed as pg ml-1 by reference to this standard.
Histology
Multiple liver biopsies were taken before and directly after IHP 
and upon sacrifice at 4 -6  weeks post-operatively. The tissue 
samples were fixed in formaldehyde and embedded in pari 
Five-micrometre sections were stained with haematoxylin and 
eosin (HE). In addition, samples were taken from all animals in 
preparation for electronmicroscopy (EM).
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Statistics
Comparisons within and between groups were made by analysis o f  
variance for repeated measurements (ANOVA) or by the Mest 
where appropriate. Correlations between maximum or minimum  
levels o f  parameters were calculated as Spearmann’s rank correla­
tions. The significance level was taken as a probability (two-sided) 
o f  < 0.05.
100 000
RESULTS
The duration o f  the operation ranged from 4 to 7 h (median 6 h). In 
all animals, a stable perfusion was achieved with no apparent 
leakage as demonstrated by the fluorescein dye injection. Further 
technical details are summarized in Table 1. As indicated by the 
oxygen saturation levels in the perfusate, adequate tissue perfusion 
was attained in all cases. In addition, the measured flow rates in 
the PV did not differ significantly before and after IHP in all 
groups. Median blood loss was 500 ml (range 300-1500  ml), 
including blood lost in the perfusion circuit. All pigs survived the 
operation. One animal in the TNF-alone group died on the first 
post-operative day. At necropsy, clear, serosanguinous fluid was 
observed in the abdomen without evidence of portal hyper­
tension/thrombosis or surgical haemorrhage. One pig in 
TNF/melphalan group underwent relaparotomy for hernia cicatri- 
calis 2 weeks after IHP; one pig in the TNF-alone group developed 
pneumonia with elevated leucocyte counts 4  weeks after perfu­
sion. At the time o f  necropsy, all remaining animals were in good  
general condition, with weights ranging from 30 to 40 kg. In fact, 
4  weeks after IHP, all surviving animals had gained weight.
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Figure 2 Perfusate (A) and systemic (B) TNF-a levels (pg ml"1) as a function 
of time before, during and after IHP in pigs. TNF; *, TNF/melphalan;
, control
groups. In all groups, serum albumin levels decreased to a nadir of 
approximately 22 g 1 1 on the first post-operative day and returned 
to normal vz within the next 7 -1 4  days, (Figure 1). 
Haemoglobin and haematocrit remained normal throughout the 
follow-up period (data not shown). In contrast, platelet counts 
decreased slightly, but not significantly, during the first post­
operative day and normalized within 3 -7  days.
T N F -a  levels in the perfusate o f  the pigs in the TNF-alone 
group increased to a median o f  5.0 x 1()(’ pg ml 1 (range 4 .9 -  
6.3 x 10h); compared with 5.2 x  10h pg ml 1 (5 .1 -6 .6  pg ml ') in the 
TNF/melphalan group. These perfusate T N F -a  levels remained 
virtually stable throughout the 1-h perfusion period. Perfusate
not er significantly between T N F -a in the group remained normal (i.e.
Macroscopic post-mortem examination did not reveal any intra­
abdominal or intrathoracic abnormalities.
In all animals, IHP resulted in significant elevations o f  ASAT,
ALAT, LDH and alkaline phosphatase levels, with peak values 
occurring on day 1 post-operatively (Figure 1). Transaminase 
levels returned to normal within the first 7—10 post-operative days, 
while alkaline phosphatase and LDH remained slightly elevated 
throughout the observation period. Total bilirubin values remained 
within the normal range (Figure 1), as did the serum values o f  
urea, y-GT and creatinin (data not shown). There were no signifi­
cant differences in peak values or kinetics between the three
< 5 pg ml ') during IHP (Figure 2). At I = 0 (i.e. at the beginning of 
the perfusion), all animals displayed normal systemic TNF-a  
levels. During IHP, systemic T N F -a  levels in the control group 
increased to a median of 12 pg mb' (8 .9 -15  pg ml-1) at / = 60 min, 
compared with 76 pg m l'1 (41—120 pg m l 1) in the TNF-alone 
group and 139 pg m l'1 (3 4 -1 9 7  pg ml ‘) in the TNF/melphalan 
group. These figures indicate that, in both experimental groups, 
cumul ative systemic leakage o f  T N F -a  from the perfusate was less 
than 0.02% during the 60-min perfusion. However, following 
washout and decannulation at the end o f  the perfusion, systemic 
T N F -a  levels increased significantly in the TNF-alone group
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and the TNF/melphalan group, with an peak levels of
3.2 x  10-1 pg m l'1 and 17 x  10-1 pg ml 1 respectively (Figure 2). 
These peak levels occurred between 1 and 30 min (median 10 min) 
after washout and returned to normal within 480 min after IHP. 
Again, there were no significant differences between the two 
experimental groups. Systemic post-perfusion T N F -a  levels in the 
control animals rose slightly, but not significantly, to a maximum  
value o f  26 pg ml-1 at t -  60 min after washout. None o f  the biliary 
samples evaluated contained detectable levels of TNF-a.
Compared with pre-perfusion histology, microscopic exam ina­
tion of HE-stained sections taken directly after perfusion showed  
mild sinusoidal dilatation as well as septal oedema with sporadic 
intraseptal polymorphonuclear cell (PMN) infiltration. These find­
ings were documented in all animals, including the controls. There 
was no apparent hepatocellular damage or parenchymal necrosis. 
At 4 - 6  weeks after IHP, all microscopical sections revealed 
normal pig liver histology (on both HE and EM), with the excep­
tion o f  sporadic PMN infiltrates in the liver parenchyma. The  
septal oedema and sporadic septal infiltration had disappeared in 
all specimens investigated. Again, these findings were similar in 
all three groups.
r
DISCUSSION
The data presented here demonstrate that, in the pig model used, 
hyperthermic isolated perfusion o f  the liver via both the H A  and 
the PV is technically feasible and appears to be a safe procedure. 
Nevertheless, the current IHP technique still involves a large 
operation, as illustrated by the median duration of 6 h and the one  
post-operative death. Additional modifications, including the use 
of balloon catheters, are therefore being studied at present. 
Temporary exposure of normal porcine liver parenchyma to high- 
dose rhTNF-a, with and without melphalan, in combination with  
hyperthermia is well tolerated and results in mild, transient 
hepatotoxicity. This was illustrated by early elevation o f  liver 
enzyme levels, followed by a spontaneous return to normal levels. 
On histological examination, immediate post-perfusion changes  
included sinusoidal dilatation and mild septal oedema, without any 
signs o f hepatocellular injury. Sections taken 4 - 6  weeks after IHP 
evealed sporadic, periportal infiltrates in otherwise normal 
hepatic parenchyma. Most biochemical and histological alterations 
following IHP were similar in both control and experimental 
animals. This suggests that the mild hepatotoxic phenomena  
observed were primarily caused by the IHP procedure itself and 
that the addition o f  the drugs used, in particular rhTNF-a, does not 
lead to additional hepatotoxicity. These findings are in agreement 
with those reported on IHP with hyperthermia and/or standard 
chemotherapeutics (Skibba, 1983, 1988; Sindelar, 1985; Van do 
Velde, 1986; Aigner, 1988; Hafstrom 1994).
Complete vascular isolation o f  the liver during IHP is essential to 
avoid systemic exposure to high doses o f  anti tumoral agents. 
Previous studies on IHP in large animals, using somewhat different 
methodologies, have mentioned technical difficulties resulting in 
incomplete vascular isolation and systemic leakage o f  drugs. Van de 
Velde et al (1986) reported leakage in 3 out o f 15 pigs treated with 
IHP, whereas Sindelar et al (1985) encountered incomplete vascular 
isolation in 2 out o f  10 pigs, resulting in severe systemic drug-asso­
ciated toxicity and death. In these studies, either a passive external 
or an internal venous shunt was employed to drain distal portal and 
lower body blood. In view o f  their findings, we modified the IHP 
technique in an attempt to minimize leakage. This modification
involved the introduction o f  a separate, second active circuit which 
consisted o f  a pump-aided, extracorporeal veno-venous bypass 
shunt (VVB) connecting cannulas in the distal PV and infrarenal 
IVC with the external jugular vein. Besides simplifying the hepatic 
perfusion circuit in this manner (as opposed to internal venous 
shunts), the VVB has the additional advantage o f  more efficiently 
shunting blood from the lower body, kidneys and intestines to the 
heart. As a result, the cardiac venous return increases, thereby
the procedure. In 
fact, we did not observe any haemodynamic instability during our
s in pigs, generally considered to be haemodynamieally 
sensitive. Moreover, we have been able to detect that there was no 
significant leakage from the liver perfusion circuit to the systemic
circulation. This was achieved using either o f two qualitative 
methods, i.e. observing fluorescent dye distribution or monitoring 
perfusate reservoir levels. This was confirmed in a quantitative 
manner by analysing, during the vascular isolation period, systemic 
levels o f  TN F-a, which remained approximately lour orders o f  
magnitude lower than perfusate levels. In addition, all pigs survived 
the procedure and no animal demonstrated any of the known 
systemic side-effects of rhTNF-a in pigs during and after IHP 
(Leighton, 1991;Truog, 1992).
However, following IHP and washout, an additional rise in 
system ic T N F -a  levels was seen upon restoration of vascular 
continuity. Although well below toxic concentrations o f  rhTNF in 
the pig, this phenomenon still has to be accounted for. It is possible 
that the washout procedure was not sufficiently effective in 
removing all remaining T N F -a  from the perfusate. This may be 
particularly true in the non-tumour-bearing pig liver, in which  
virtually no TNF-uptake was observed during IHP, as judged by 
perfusate T N F -a  levels (Figure 2).
There is no consensus on the route o f infusion (HA v.v PV vs 
both). Normal hepatic parenchyma receives most o f  its blood 
supply from branches of the PV and to a much lesser extent from 
the HA. In contrast, the blood supply o f  hepatic metastases is 
reported to rely almost entirely on the HA (Strohmeyer, 1986).
Consequently, most regional i 
HA. More re
is have been made using
, however, attention has been drawn to the PV 
as very small liver tumours (< 5 mm), as well as the outer rim o f  
larger hepatic metastases, are fed mainly by portal branches 
(Archer, 1989). In addition, most colorectal tumours are drained 
via the PV, suggesting that spreading tumour cells will first prolif­
erate in the portal system. Thus, by using the HA as well as the PV, 
drugs will reach both established and newly formed (micro) metas­
tases. Taking this into consideration, we performed IHP via both 
the HA as well as the PV. However, as most normal hepatic 
parenchyme tissue is supplied primarily by the PV, it could be
that infusion via the PV 
Indeed, Boddie et al (
ce
via the PV and demonstrated significant hepatic damage, In accor­
dance with most other reports on IHP, we have not been able to 
confirm these findings (Skibba, 1983, 1988; Sindelar, 1985; Van 
de Velde, 1986; Aigner, 1988; Hafstrom,
At present, it is unknown which drug, or combination o f  dings, 
would provide antitumoral efficacy in the IHP setting. T N F -a  with 
and without melphalan was selected for this study based on its clin­
ical success (100% limb salvage and a 90% overall response) in 
isolated limb perfusions for irresectable melanoma and sarcoma
(Eggermont . As at least % i
tumour effect o f  T N F-a relies on the
r \  M  t %
* fc vessels, irrespective of tumour (Watanabe,
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1988; Renard, 1994; Cid, 1994), we reasoned that this combination 
might well be effective against colorectal hepatic metastases. 
Indeed, Van der Schelling et al ( 1992) have recently shown that 
intratuinoral administration of rhTNF-a, under ultrasonographic 
guidance, was able to stabilize disease in eight patients with hepatic 
metastases at the cost of minimal systemic symptoms. As demon­
strated by Mavligit et al (1992), HA infusion of rhTNF-a permits a 
more than sixfold dose increase of the maximum tolerated systemic 
(i.v.) dose before adverse systemic side-effects are noted. In this 
setting, TNF-a was found to induce tumour regression in approxi­
mately 30% of patients with irresectable colorectal liver metastases 
(Mavligt, 1992). Because of the synergy between melphalan and 
TNF-a, as demonstrated in earlier reports (Eggermont, 1996a,6; 
Lienard, 1994), melphalan was chosen over 5-FU, the drug most 
frequently used in conventional regimens against colorectal (liver) 
metastases. For reasons of comprehensiveness, we also performed 
IHP with TNF-a and 5-FU in two pigs. No mortality was encoun­
tered, and (hepatic) response patterns were identical to the ones 
described above (data not shown).
On the other hand, Kahky et al (1990) have shown that intra- 
portal administration of 100 jug kg'1 day1 rhTNF-a results in 
100% mortality in rats. Histological examination in their study 
revealed mild passive congestion of the liver combined with 
severe pulmonary oedema. As systemic administration of the same 
dose of rhTNF-a did not result in any deaths, it is unlikely that the 
high mortality after intraportal injection was caused solely by 
TNF-a (Kahky, 1990). TNF-a has been documented to induce the 
production of various cytokines (including IL-l, IL-6 and TNF-a) 
by macrophages (i.e. Kupffer cells) (Shirahama, 1988; Busam, 
1990). As the vast majority of hepatic Kupffer cells are situated in 
the (peri) portal area, such a secondary cytokine release might 
explain the observed mortality. As far as we can judge, IHP with 
rhTNF-a and melphalan in the healthy pig does not lead to such 
dramatic cytokine-related side-effects.
In conclusion, hyperthermic IHP with rhTNF-a and melphalan 
in pigs is technically feasible, resulting in minimal systemic 
leakage of drugs and mild, transient hepatotoxicity. The addition 
of rhTNF-a and melphalan in the perfusate does not lead to addi­
tional hepatotoxic side-effects. As pig liver physiology is similar 
to humans, IHP with rhTNF-a and melphalan should be consid­
ered for phase I evaluation in patients with irresectable hepatic 
malignancy.
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